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Recent studies have shown renoprotective effects of the
peroxisome proliferator-activated receptor-a (PPAR-a), but its
role in kidney fibrosis is unknown. In order to gain insight
into this, we examined the effect of a novel PPAR-a agonist,
BAY PP1, in two rat models of renal fibrosis: unilateral
ureteral obstruction and the 5/6 nephrectomy. In healthy
animals, PPAR-a was expressed in tubular but not in
interstitial cells. Upon induction of fibrosis, PPAR-a was
significantly downregulated, and treatment with BAY PP1
significantly restored its expression. During ureteral
obstruction, treatment with BAY PP1 significantly reduced
tubulointerstitial fibrosis, proliferation of interstitial
fibroblasts, and TGF-b1 expression. Treatment with a less
potent PPAR-a agonist, fenofibrate, had no effects. Treatment
with BAY PP1, initiated in established disease in the 5/6
nephrectomy, halted the decline of renal function and
significantly ameliorated renal fibrosis. In vitro, BAY PP1 had
no direct effect on renal fibroblasts but reduced collagen,
fibronectin, and TGF-b1 expression in tubular cells.
Conditioned media of BAY PP1-treated tubular cells reduced
fibroblast proliferation. Thus, renal fibrosis is characterized by
a reduction of PPAR-a expression, and treatment with BAY
PP1 restores PPAR-a expression and ameliorates renal
fibrosis by modulating the cross-talk between tubular cells
and fibroblasts. Hence, potent PPAR-a agonists might be
useful in the treatment of renal fibrosis.
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Persisting uncontrolled fibrosis is a pathological process in
which functional tissue is replaced by permanent tissue scars.
A good example is renal tubulointerstitial fibrosis, the
uniform and common end point of virtually all chronic
kidney diseases. The number of patients with chronic kidney
disease, who are at high risk for cardiovascular complications
and, ultimately, for end-stage renal disease, is steadily
increasing. We currently lack effective therapies to battle
renal fibrosis.1 Therefore, identification of novel and effective
therapeutic targets is of great importance.
Peroxisome proliferator-activated receptor-a (PPAR-a)
belongs to a superfamily of ligand-activated nuclear hormone
receptors. PPAR-a functions as a transcription factor
regulating expression of genes involved in various processes,
for example, energy metabolism (mainly of lipids and
glucose), cellular differentiation, and stimulation of peroxi-
some proliferation.2 In clinical practice, PPAR-a agonists,
such as fibrates, are used as lipid-lowering drugs. The kidney
is one of the organs with the most abundant PPAR-a
expression.2 A strong expression was found in proximal
tubular cells and medullary thick ascending limbs and a less
prominent expression in mesangial cells.3–6 A renoprotective
function of PPAR-a was suggested by studies in various
animal models of renal diseases.2,7–13 Compared with wild-
type (WT) mice, PPAR-a knockout mice had aggravated
acute renal failure in cisplatin-induced and ischemia–reper-
fusion nephropathies.7,8 The PPAR-a agonist, fenofibrate,
ameliorated diabetic nephropathy in db/db mice and Zucker
diabetic fatty rats, improved glycemic control, and reduced
blood pressure, respectively.9,10 PPAR-a was found to be an
important regulator of proximal tubular homeostasis in
physiological and proteinuric conditions.11–13 In mesangial
cells, PPAR-a agonists reduced the production of transform-
ing growth factor-b1 (TGF-b1) and extracellular matrix
(ECM).5,9 Furthermore, in models of heart failure and liver
fibrosis, PPAR-a was shown to have antifibrotic proper-
ties.14–18 The other member of the PPAR family, PPAR-g, is
known to have antifibrotic properties in renal diseases.2,19
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The studies mentioned focused on metabolic disease
models but, to our knowledge, no study so far has examined
the role of PPAR-a agonists in renal fibrosis. Here, we
analyzed the expression of PPAR-a and tested the effects of
PPAR-a agonists in established animal models of tubuloin-
terstitial fibrosis, unilateral ureteral obstruction (UUO), and
the remnant kidney model. We also tested the effects of
PPAR-a agonists in vitro in renal interstitial fibroblasts and
tubular epithelial cells.20–22
RESULTS
Selectivity of BAY PP1 and fenofibrate
The potency and selectivity of BAY PP1 (2-[(4-{[(2-
Methoxyethyl){6-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl}
amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid) has
been tested on Chinese hamster ovary (CHO) cells expressing
the ligand-binding domain of human PPAR receptors
fused to the binding domain of the yeast transcription factor
GAL4. BAY PP1 is a highly selective and potent PPAR-a
agonist with half-maximal effective concentration (EC50)
values of 45 nmol/l on PPAR-a, 410 mmol/l on PPAR-g, and
48mmol/l on PPAR-d (Table 1 and Supplementary Figure S1
online). Fenofibrate is a much weaker PPAR-a agonist with
an EC50 of 17 mmol/l (Table 1).
Expression of PPAR-a in renal fibrosis
We analyzed the expression of PPAR-a in healthy kidneys and
in a widely used primary model of tubulointerstitial fibrosis, in
the UUO with or without treatment with PPAR-a agonists
BAY PP1 and fenofibrate (Figure 1a). In the obstructed kidneys
of placebo-administered UUO rats, the mRNA expression of
PPAR-a was significantly reduced by 93.7% (Figure 1b). The
treatment with fenofibrate significantly increased PPAR-a
expression, and the treatment with BAY PP1 even restored it
to nearly normal levels (Figure 1b). The target gene of PPAR-a,
CYP4a1 (cytochrome P450, family 4, subfamily a, polypeptide 1
or arachidonic acid monooxygenase), is significantly increased
in the obstructed kidneys of placebo-administered rats
compared with healthy sham kidneys (Figure 1c). Treatment
with both PPAR-a agonists led to a nonsignificant increase of
CYP4a1 mRNA expression compared with obstructed kidneys
of placebo-administered rats (Figure 1c). On the protein level,
as measured by western blot analysis, a PPAR-a-specific band
was detected at 52 kD, in line with the predicted molecular
weight (Figure 1e) and previous studies.9 PPAR-a was
significantly reduced in placebo-treated obstructed kidneys
compared with healthy sham kidneys (Figure 1d and e).
Interestingly, fenofibrate had no significant effect on the
PPAR-a expression, whereas BAY PP1 treatment nearly
normalized its expression (Figure 1d and e).
PPAR-a expression was uniformly localized in the
cytoplasm of cortical tubular cells in healthy kidneys (Figure
1f and g). Only negligible traces of staining were found in the
nuclei, in thin parts of the nephron, collecting ducts, and the
tubulointerstitium (Figure 1g). In obstructed kidneys, in line
with our mRNA and western blot data, PPAR-a expression
was significantly reduced, mostly in dilated and atrophied
tubules (Figure 1h and i). Interestingly, some interstitial
cells, most likely leukocytes, showed positive staining
(arrowhead in Figure 1i). Compared with placebo-treated
animals, fenofibrate led to only a very slight increase in
PPAR-a staining (Figure 1j). BAY PP1-treated animals had a
much more robust increase in PPAR-a expression, again in
line with mRNA and western blot data (Figure 1k). There was
no nonspecific staining in the negative control (Figure 1l).
To further confirm our results, we have used the rat
remnant kidney model, in which renal fibrosis develops after
ablation of 5/6 of renal parenchyma (Figure 2a). In line with
previous studies,23,24 the PPAR-a expression was significantly
downregulated in 5/6 nephrectomized rats compared
with sham-operated animals (Figure 2b and c). In addition,
in accordance with results in the UUO model, BAY PP1
significantly increased PPAR-a expression in 5/6 nephrecto-
mized rats (Figure 2b and c). These data were further
supported by the immunofluorescence staining: uniform
tubular PPAR-a expression was found in cortical tubules of
healthy animals, whereas in remnant kidneys it was markedly
reduced (Figure 2d–f). Treatment with BAY PP1 significantly
restored PPAR-a expression (Figure 2e).
Obstructed kidneys developed marked renal fibrosis
Compared with sham-operated animals, or the correspond-
ing contralateral unobstructed kidneys, UUO resulted in
a significant increase in all hallmarks of renal fibrosis:
accumulation of the ECM proteins collagen types I, III,
and IV, and fibronectin, increased expression of a-smooth
muscle actin (a-SMA) as a marker of activated (myo-)
fibroblasts and the mesenchymal marker vimentin, higher
infiltration with monocytes/macrophages (Figures 3 and 4),
and prominent proliferation of interstitial and tubular cells
(Figures 4 and 5). None of the PPAR-a agonists affected the
unobstructed kidneys (Figures 3 and 5).
PPAR-a agonist BAY PP1, but not fenofibrate, reduced
fibrosis in UUO
Compared with placebo-treated rats, in obstructed kidneys,
only BAY PP1, but not fenofibrate, significantly reduced the
Table 1 | Potency and selectivity of BAY PP1 and fenofibrate
GAL4 transactivation assay, EC50 (lmol/l)
PPAR a c d
BAY PP1 0.045 410 8
Fenofibrate 17 4300 4300
Abbreviations: BAY PP1, 2-[(4-[(2-Methoxyethyl)6-[3-(trifluoromethyl)phenyl]pyrimi-
din-4-ylamino]methylphenyl)sulfanyl]-2-methylpropanoic acid; EC50, half-maximal
effective concentration; PPAR, peroxisome proliferator-activated receptor.
A chimeric system was used, in which the ligand-binding domain (LBD) of the
human PPAR protein is fused to the DNA-binding domain of the yeast transcription
factor GAL4. The GAL4-PPAR-a, -g, or -d LBD fusion construct plus a reporter
construct containing GAL4-binding sites in front of the luciferase gene were co-
transfected and stably expressed in Chinese hamster ovary cells. The PPAR-LBD-
mediated induction of luciferase gene expression correlates with relative light units
(RLU) detected by a standard luciferase assay upon BAY PP1 or fenofibrate
stimulation (for further details, see Materials and Methods section).
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expression of extracellular proteins: collagen type III and IV
proteins or collagen type I and fibronectin mRNA by 31%,
26%, 73%, and 81% (Figures 3a–d and 4), respectively.
These results were further confirmed by showing that BAY
PP1, but not fenofibrate, significantly reduced whole cortical
collagen and collagen type I content, as assessed by Sircol
assay (Figure 3e) and western blotting (Figure 3j), respec-
tively. It is noteworthy that these methods are highly
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Figure 1 | Expression of peroxisome proliferator-activated receptor-a (PPAR-a) in unilateral ureteral obstruction (UUO) model of
renal fibrosis and its modulation by BAY PP1 and fenofibrate. (a) We first examined the PPAR-a expression in the UUO model 5 days
after obstruction. (b) Compared with healthy sham-operated rats (SHAM), placebo-treated animals (PLAC) had nearly undetectable PPAR-a
mRNA. Both fenofibrate (FF) and BAY PP1 (BAY) significantly increased PPAR-a mRNA, BAY to nearly normal levels. (c) These data were
largely corroborated by mRNA of the PPAR-a target gene CYP4a1. Western blotting analysis of PPAR-a showed a specific band at 52 kD
(predicted molecular weight 52 kD; upper bands in e). (d) Densitometry of the PPAR-a western blot showed a significant reduction in PPAR-
a protein expression in the UUO. Equal protein loading was confirmed using glyceraldehyde 3-phosphate dehydrogenase (GAPDH; 39 kD;
lower bands in e). (d) Whereas BAY nearly normalized the expression of PPAR-a, FF had no significant effect. (f–k) Immunofluorescent
staining for PPAR-a (red/Cy3; nuclei counterstained with blue/4,6-diamidino-2-phenylindole (DAPI)) confirmed the results of western
blotting. In SHAM animals, PPAR-a was localized to tubular cells (arrows in g) and no significant staining was found in interstitial cells
(arrowhead in g), collecting ducts (asterisk in g), and thin parts of the nephron (f and g; g shows larger magnification of the area indicated in
f by the white quadrangle). The staining was cytoplasmic; only negligible traces of nuclear signal were observed. Untreated UUO rats had
significantly reduced expression of PPAR-a in tubular cells (arrow; h, i; i shows larger magnification of the area indicated in h by the white
quadrangle). Interestingly, some interstitial cells, most likely leukocytes, showed cytoplasmic PPAR-a expression (arrowhead in i). (j) Whereas
FF led to only a very slight increase in PPAR-a signal, (k) BAY treatment significantly restored PPAR-a expression. (l) No detectable red
fluorescence was observed in the negative control. Original magnifications  400 (f, h, j–l), digital magnification (g, i). Data are
means±s.e.m. *Po0.05 vs SHAM; **Po0.01 vs SHAM; #Po0.05 BAY vs PLAC. Data on mRNA expression show fold change; expression in
sham-operated kidney was arbitrarily set as 1. Data on PPAR-a western blotting show relative optical intensity (densitometry); expression in
sham-operated kidneys was arbitrarily set as 100%. BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-(trifluoromethyl)phenyl]pyrimidin-4-
yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; CYP4a1, cytochrome P450, family 4, subfamily a, polypeptide 1 or arachidonic acid
monooxygenase; Rel., relative.
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complementary: the data of the Sircol assay and the area
stained positively for collagen types III and IV correlated
tightly and highly significantly (r¼ 0.714, P¼ 0.00002 and
r¼ 0.812, P¼ 0.00001, respectively). The marker of myo-
fibroblasts, a-SMA, was not affected at the protein level
(Figures 3f and 4), but its mRNA expression was significantly
reduced in the obstructed kidneys of BAY PP1-treated
rats (77%, Figure 3g). The mRNA of vimentin was not
significantly reduced by BAY PP1 (42%, P¼ 0.084, Figure
3h). Infiltration of monocytes/macrophages was not altered
by BAY PP1 and was even significantly increased by
fenofibrate (Figures 3i and 4). In line with these findings,
the mRNA expression of myeloperoxidase was not altered
by any of the treatments (data not shown). The expression
of TGF-b1 in renal cortex of obstructed kidneys was signif-
icantly reduced by BAY PP1 (34%), but not by feno-
fibrate (Figure 3k).
Effects of PPAR-a agonists on cell proliferation in UUO
BAY PP1 treatment reduced the number of interstitial
proliferating cell nuclear antigen (PCNA)-positive cells
significantly and mitotic figures nonsignificantly (52%
and 42%, respectively, Figures 4 and 5a and b). BAY PP1
significantly lowered the number of cells double positive for
the proliferation marker PCNA and the marker of fibroblasts
and pericytes, platelet-derived growth factor receptor-b
(PDGFR-b; 66%, Figures 4 and 5c). Fenofibrate had no
effect on any of these parameters (Figures 4 and 5). Neither of
the PPAR-a agonists had any significant effects on tubular
mitotic figures or tubular PCNA-positive cells (Figures 4, 5d
and e).
Biochemical and inflammatory parameters in the UUO model
Parameters of renal function (plasma urea and creatinine
concentrations) and left kidney weight were significantly
increased in the UUO groups compared with the sham-
operated rats (Table 2). No difference between the placebo,
BAY PP1, and fenofibrate groups were found. Unobstructed
kidney weight was similar between the groups (Table 2).
No difference in systemic inflammatory markers, that is,
leukocyte counts, plasma advanced oxidation protein prod-
ucts, tumor necrosis factor-a, and interleukin-6 concen-
trations, were found (data not shown). Plasma sodium,
potassium, aspartate aminotransferase, and alanine amino-
transferase were within the normal range and comparable in
all groups (data not shown). No differences in the blood
counts were revealed (data not shown).
BAY PP1 ameliorates fibrosis and loss of renal function in rat
remnant kidney model
To investigate a more general effect of BAY PP1 on renal
fibrosis and renal function, we have used a different model of
renal fibrosis, the rat remnant kidney model (Figure 2a).
Compared with sham-operated animals, rats with remnant
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Figure 2 | Expression of peroxisome proliferator-activated receptor-a (PPAR-a) in the remnant kidney model of renal fibrosis and its
modulation by BAY PP1. We next examined the PPAR-a expression in another model of renal fibrosis, the 5/6 nephrectomy (remnant
kidney) model in rats. (a) In this model, we started the treatment at already established disease; that is, at day 42 after induction of the
disease. (b, c) Compared with healthy sham-operated rats (SHAM), placebo-treated animals (PLAC) had significantly reduced PPAR-a protein
expression, as measured by densitometry of western blot for PPAR-a. Compared with PLAC, BAY PP1 (BAY) significantly increased
PPAR-a expression. Equal protein loading was confirmed using GAPDH (39 kD; lower bands in c). These data were corroborated by
immunofluorescent staining for PPAR-a (red/Cy3; nuclei counterstained with blue/4,6-diamidino-2-phenylindole (DAPI); d–f). Uniform
tubular expression of PPAR-a was found in (f) SHAM animals, (d) whereas it was largely lost in untreated rats with remnant kidney.
(e) Treatment with BAY markedly restored tubular PPAR-a expression. Original magnifications  400 (d–f). Data are means±s.e.m. *Po0.05
vs SHAM; #Po0.05 BAY vs PLAC. Data on PPAR-a western blotting show relative optical intensity (densitometry); expression in
sham-operated kidneys was arbitrarily set as 100%. BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-(trifluoromethyl)phenyl]pyrimidin-
4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; Nx, nephrectomy; Rel., relative; UniNx, uninephrectomy.
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Figure 3 | Treatment with BAY PP1, but not fenofibrate, significantly reduced tubulointerstitial fibrosis in rats with unilateral
ureteral obstruction (UUO). Compared with sham-operated rats (SHAM) and contralateral nonobstructed kidneys (white bars),
UUO resulted in a marked tubulointerstitial fibrosis. Compared with placebo-treated UUO rats (PLAC), the peroxisome proliferator-activated
receptor-a (PPAR-a) agonist fenofibrate (FF) had no effect on the determined parameters, whereas the PPAR-a agonist BAY PP1 (BAY)
significantly reduced the accumulation of extracellular matrix proteins; that is, collagen (a) type III and (b) IV proteins (measured by
computer-based morphometry of immunohistochemical stainings), and (c) collagen type I and (d) fibronectin mRNA expression.
This was confirmed by content of cortical collagens, and more specifically of cortical collagen type I content measured by (e) Sircol assay,
and by (j) western blotting (band at 150 kD), respectively. Equal protein loading of western blots was confirmed using glyceraldehyde
3-phosphate dehydrogenase (GAPDH; 39 kD; lower bands in j). BAY reduced the (g) marker of activated (myo-) fibroblasts, a-SMA, on mRNA,
(f) but, at this stage of the disease, not on the protein level. (h) Vimentin was slightly and nonsignificantly reduced in the BAY PP1 group.
(i) Compared with PLAC, BAY had no effect on tubulointerstitial infiltration by monocytes/macrophages, but treatment with FF significantly
increased it. (k) Renal cortical TGF-b1 measured by an enzyme-linked immunosorbent assay (ELISA) was significantly reduced in
BAY-treated animals, but not in FF-treated animals. It is noteworthy that none of the treatments affected the nonobstructed kidneys.
Black bars represent data of obstructed left kidneys (and left kidneys of sham-operated rats); white bars show data of contralateral
nonobstructed kidneys. Data are means±s.e.m. *Po0.05 vs SHAM; **Po0.01 vs SHAM; ***Po0.001 vs SHAM; #Po0.05 BAY vs PLAC;
##Po0.01 BAY vs PLAC; &Po0.05 FF vs PLAC and BAY. Data on mRNA expression show fold change; expression in sham-operated
kidney was arbitrarily set as 1. Data on collagen type I western blotting show relative optical intensity (densitometry); expression
in sham-operated kidneys was arbitrarily set as 100%. a-SMA, a-smooth muscle actin; BAY PP1, 2-[(4-{[(2-Methoxyethyl)
{6-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; Mo/Mj, monocytes/macrophages
(ED-1þ cells); TGF-b1, transforming growth factor-b1.
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kidneys developed marked renal fibrosis paralleled with a
decline in renal function (Figure 6). Importantly, treat-
ment with BAY PP1 or vehicle was initiated in a state with
already established loss of renal function (day 42, Figure 2a).
A 17-day-long treatment with BAY PP1 significantly halted
the rise in plasma creatinine (Figure 6a) and reduced the loss
of GFR as measured by creatinine clearance (Figure 6b). This
was paralleled by a significant reduction of the tubulo-
interstitial injury score (Figure 6c). Deposition of collagen
was significantly reduced in BAY-treated animals, as assessed
by Sircol assay (Figure 6d), cortical area stained for collagen
type I (Figure 6e), as well as mRNA expression of collagen
type 1 (Figure 6f). The antifibrotic effects of BAY PP1 were
further confirmed by western blotting analysis for collagen
type I (Figure 6g). As in the UUO model, Sircol assay
and computer morphometry of collagen type I immuno-
histochemistry results correlated tightly and significantly
(r¼ 0.659, P¼ 0.002).
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Figure 4 |Representative photomicrographs of UUO and sham kidneys. Rows from left to right depict the obstructed kidneys of
placebo (PLAC)-, fenofibrate (FF)-, and BAY PP1 (BAY)-treated rats with UUO and healthy kidneys from sham-operated rats (SHAM). In PAS
staining, the arrows point to interstitial mitotic figures. In the double staining, PCNA is shown in brown and PDGFR-b in blue. The
quantifications of these stainings are shown in Figures 3 and 5. Original magnifications  200 (Col. III, Col. IV, a-SMA, and Mo/Mj),  400
(PAS, PCNA, and PDGFR-b). a-SMA, a-smooth muscle actin; BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-(trifluoromethyl)phenyl]pyrimidin-
4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; Col., collagen; Mo/Mj, monocytes/macrophages; PAS, periodic acid
Schiff staining; PCNA, proliferating cell nuclear antigen; PDGFR-b, platelet-derived growth factor receptor-b; UUO, unilateral ureteral
obstruction.
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In line with the results in the UUO model, BAY PP1
treatment resulted in a significant reduction of prolifer-
ating interstitial cells (Figure 7a) but not of tubular cells
(Figure 7b). Similar to the UUO model, no significant effect
on infiltration by monocytes/macrophages was observed
(Figure 7c). No difference in the number of apoptotic
cells was found between the placebo- and BAY PP1-treated
rats (Figure 7d). The renal cortical expression of TGF-b1
mRNA was significantly reduced in BAY PP1-treated animals
(Figure 7e), whereas the reduction on protein level was not
significant (Figure 7f, P¼ 0.08).
There were no significant differences between the BAY
PP1- and vehicle-treated animals regarding body weight,
remnant kidney weight, blood pressure, and food or water
consumption (data not shown).
Genetic PPAR-a deficiency had no effect on renal fibrosis in
mice with UUO
To further analyze the role of PPAR-a in renal fibrosis,
we have performed UUO in PPAR-a-deficient (PPAR-a/)
and WT mice. All analyzed indices of renal fibrosis were
significantly increased in obstructed kidneys compared
with contralateral kidneys (Table 3). However, no significant
differences between PPAR-a/ and WT mice were observed
(Table 3).
In vitro experiments
BAY PP1 had no direct effect on cell proliferation of rat renal
fibroblasts (NRK-49F) or tubular cells (NRK-52E; Figure 8a
and b). Fibroblasts cultured with a conditioned medium of
BAY PP1-treated tubular cells had significantly reduced
proliferation compared with cells cultured with conditioned
media of untreated tubular cells (34%, Figure 8c).
Western blotting of PPAR-a revealed no detectable band
in renal fibroblasts (Figure 9a and c), whereas it was readily
detectable in tubular cells (Figure 9b and d). In tubular cells,
addition of the profibrotic cytokine TGF-b1 reduced PPAR-a
expression by 31% compared with unstimulated cells.
Treatment with BAY PP1 significantly increased PPAR-a
expression by almost 20% compared with TGF-b1-stimulated
cells (Figure 9b and d).
Furthermore, treatment of tubular cells with BAY PP1
significantly reduced expression of collagen and fibronectin
on protein and mRNA levels (Figure 10c–e). The expression
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Figure 5 | Treatment with BAY PP1, but not fenofibrate (FF), reduced proliferation of interstitial cells but had no effect on tubular
cell proliferation in rats with unilateral ureteral obstruction (UUO). Compared with sham-operated rats (SHAM) and contralateral
nonobstructed kidneys, proliferation of interstitial and tubular cells was significantly increased in obstructed kidneys. Treatment with BAY
PP1 (BAY), but not with fenofibrate, reduced the (a) proliferation rate counted as mitotic figures or (b) the number of PCNA-positive cells.
(c) Double immunostaining showed that BAY reduced the number of proliferating PDGFR-b/PCNA-positive fibroblasts. Neither the
treatment with BAY nor with FF affected (d) tubular mitotic figures, or (e) the number of PCNA-positive tubular cells. Black bars represent
data of obstructed left kidneys (and left kidneys of sham-operated rats); white bars show data of contralateral nonobstructed kidneys.
Data are means±s.e.m. *Po0.05 vs SHAM; **Po0.01 vs SHAM; #Po0.05 BAY vs PLAC; ##Po0.01 BAY vs PLAC. BAY PP1, 2-[(4-{[(2-
Methoxyethyl){6-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; HPF, high-power field;
PCNA, proliferating cell nuclear antigen; PDGFR-b, platelet-derived growth factor receptor-b; TUNEL, terminal deoxynucleotidyl transferase-
mediated X-dUTP nick-end labeling.
Table 2 | Kidney weight and renal function in the UUO model
PLAC FF BAY SHAM
Left kidney weight/bw
( 103)
7.8±1.0 7.8±0.8 7.2±0.8 4.2±0.3*
Right kidney weight/bw
( 103)
4.6±0.4 4.9±0.3 4.8±0.4 4.1±0.2
Plasma urea (mmol/l) 7.6±1.2 7.1±1.4 8.3±1.9 5.2±1.7*
Plasma creatinine (mmol/l) 60±8 58±6 58±6 43±6*
Abbreviations: BAY, BAY PP1; bw, body weight; FF, fenofibrate; PLAC, placebo-
treated animals; SHAM, sham-operated rats; UUO, unilateral ureteral obstruction.
*Po0.05 SHAM vs all.
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of a major profibrotic cytokine, TGF-b1, was significantly
reduced on the mRNA level by BAY PP1 (Figure 10f). In line
with the in vivo findings, BAY PP1 significantly reduced
the mRNA expression of a-SMA (Figure 10g). No indication
of altered cell morphology or cell death was found upon
treatment with BAY PP1 (Figure 10a, b, and h).
In renal fibroblasts, in line with the undetectable PPAR-a
expression, BAY PP1 showed no direct effects on cell
morphology (Figure 10i and j), collagen protein or mRNA
expression (Figure 10k and l), a-SMA or TGF-b1 mRNA
expression (Figure 10m and n), and fibronectin mRNA or
protein expression (data not shown).
DISCUSSION
The major and novel finding of this study is that in two
different animal models of tubulointerstitial fibrosis, renal
PPAR-a expression was markedly reduced, and that treat-
ment with the potent and highly specific PPAR-a agonist,
BAY PP1, significantly ameliorated renal fibrosis. PPAR-a
agonist halted the decline in renal function, even if started in
already established disease, that is, in a clinically relevant
situation. These effects seemed to be mediated via restora-
tion of PPAR-a expression in tubular cells, thereby directly
affecting the tubular phenotype and the cross-talk with
interstitial fibroblasts.
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Figure 6 |Treatment with BAY PP1 preserved renal function and reduced tubulointerstitial fibrosis in rats with remnant kidneys.
Compared with sham-operated rats (SHAM), animals with remnant kidneys had significantly impaired renal function and developed
tubulointerstitial fibrosis. Compared with placebo-administered rats (PLAC), treatment with PPAR-a agonist BAY PP1 for 17 days, initiated
in already established disease, significantly (a) halted the rise in plasma creatinine and (b) improved creatinine clearance.
(c) This was paralleled in significantly improved tubulointerstitial histoarchitecture as measured by tubulointerstitial injury score.
Furthermore, BAY treatment significantly reduced the accumulation of collagens, that is, of cortical collagen content as measured by
(d) Sircol assay, of collagen type I as measured by (e) immunohistochemistry and (g) western blotting (band at 150 kD), as well as of
(f) collagen type I mRNA. Equal protein loading of the western blots was confirmed using glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; 39 kD; lower bands in g). Lower panel shows representative microphotographs of PAS and collagen type I staining in remnant
kidneys of PLAC, BAY-treated rats, and of healthy kidneys of sham-treated rats; original magnifications  200. Data are means±s.e.m.
*Po0.05 vs SHAM; **Po0.01 vs SHAM; #Po0.05 BAY vs PLAC; ##Po0.01 BAY vs PLAC. Data on mRNA expression show fold change;
expression in sham-operated kidneys was arbitrarily set as 1. Data on collagen type I western blotting show relative optical intensity
(densitometry); expression in sham-operated kidneys was arbitrarily set as 100%. BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-
(trifluoromethyl)phenyl]pyrimidin-4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; bw, body weight; Col., collagen;
PAS, periodic acid Schiff staining; PPAR-a, peroxisome proliferator-activated receptor-a.
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Metabolically active cells with high numbers of mitochon-
dria, for example, the renal tubular cells, are characterized by
a high PPAR-a expression.3,25 In line with this, immuno-
fluorescence staining of PPAR-a was localized to tubular cells,
most likely proximal, but was not detectable in nephron parts
with flat epithelium, collecting ducts, and cortical interstitial
cells. These data were further supported by western blotting
for PPAR-a in vitro in renal tubular cells and fibroblasts.
Whereas no expression was detected in fibroblasts, tubular
cells had a clear expression of PPAR-a. Localization of PPAR-
a is most widely considered to be nuclear. Even after
extensive testing (several antibodies) with fixed (several
fixatives and antigen retrievals) or unfixed renal cortical
tissue from rats, we never observed a specific nuclear staining.
However, in agreement with our study, several reports
showed similar cytoplasmic localization of PPAR-a, for
example, in human and murine macrophages and leuko-
cytes.26–28 The latter finding is in line with our observation of
interstitial cells, most likely leukocytes, with cytoplasmic
PPAR-a expression in fibrotic kidneys, characterized by
inflammatory cell infiltrates.
UUO and 5/6 nephrectomy are models of renal fibrosis
with constant tubular stress, reflected by a pronounced
tubular atrophy (flattening of cells as well as loss of
mitochondria), apoptosis, and cell loss. In our study, in
both models of fibrosis and as early as 5 days after UUO,
renal PPAR-a expression on the mRNA and protein level was
markedly reduced compared with healthy kidneys. Our data
support and further extend the findings of marked reduction
in PPAR-a expression in a 5/6 nephrectomy model.23,24 It
could be hypothesized that this reduction is due to atrophy
and damage, with subsequent or simultaneous dysregulation
of energy metabolism in tubular cells. Thus, normalization of
PPAR-a activity or restoration of its expression could be an
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Figure 7 |Treatment with BAY PP1 reduced interstitial, but
not tubular, cell proliferation in rats with remnant kidneys,
but had no effect on monocyte/macrophage infiltration or
apoptosis. Compared with sham-operated rats (SHAM), animals
with remnant kidneys had significantly increased proliferation
of interstitial and tubular cells, infiltration with monocytes/
macrophages, apoptosis, and cortical TGF-b1 expression.
Compared with placebo-administered rats (PLAC), treatment
with PPAR-a agonist BAY PP1 reduced the number of
(a) PCNA-positive interstitial cells but not (b) tubular cells.
No significant effect of BAY was observed on (c) inflammatory
infiltrates by monocytes/macrophages, or on (d) apoptosis.
Treatment with BAY significantly reduced the (e) TGF-b1 mRNA
and insignificantly the (f) total cortical protein levels. Lower panel
shows representative microphotographs of PCNA, ED-1, and
TUNEL staining in remnant kidneys of PLAC, BAY-treated rats, and
of healthy kidneys of sham-treated rats; original magnifications
 200 (PCNA and ED-1) and  400 (TUNEL). Data are
means±s.e.m. *Po0.05 vs SHAM; **Po0.01 vs SHAM; #Po0.05
BAY vs PLAC; ##Po0.01 BAY vs PLAC. Data on mRNA expression
show fold change; expression in sham-operated kidney was
arbitrarily set as 1. BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-
(trifluoromethyl)phenyl]pyrimidin-4-yl}amino]methyl}phenyl)
sulfanyl]-2-methylpropanoic acid; Mo/Mj, monocytes/
macrophages (ED-1þ cells); PCNA, proliferating cell nuclear
antigen; PPAR-a, peroxisome proliferator-activated receptor-a;
TGF-b1, transforming growth factor-b1; TUNEL, terminal
deoxynucleotidyl transferase-mediated X-dUTP nick-end
labeling.
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important target in renal fibrosis. Indeed, we showed here
that treatment of animals with renal fibrosis or incubation of
tubular cells in vitro with BAY PP1 significantly restored
tubular PPAR-a expression. This might represent a major
mechanism of the antifibrotic effects of BAY PP1. Our data
are in line with previous studies showing that PPAR-a
agonists induced PPAR promoter activity and the expression
of PPAR-a itself.9,29 We found no difference in renal fibrosis
between the PPAR-a-deficient and WTmice with UUO. Most
studies using PPAR-a-deficient mice found aggravated renal
damage in toxic and metabolic nephropathy models.8,11,12
This finding might be model specific as in UUO tubular
injury and fibrosis develop very rapidly and are prominent in
comparison with other models. However, we also suppose
that these data support the notion that PPAR-a is strongly
downregulated in UUO and renal fibrosis, resulting in
comparable fibrosis in both the PPAR-a-deficient and WT
mice.
The hallmark of kidney scarring is the accumulation of
ECM proteins, for example, scar components collagen types I
and III, or fibronectin and basal membrane components, for
example, collagen type IV.1 In our study, treatment with the
PPAR-a agonist, BAY PP1, significantly reduced the expres-
sion of these ECM proteins. We confirmed these antifibrotic
effects by four different methods, that is, on the mRNA level
(real-time PCR) as well as on the protein level (computer-
based morphometry of immunohistochemical stainings,
collagen assay, and western blots). Fibroblasts are thought
to be the principal cells responsible for ECM production in
renal fibrosis and are the prominent proliferating cell type in
the tubulointerstitium of UUO animals.1,20 PDGFR-b is a
marker of fibroblasts and pericytes. Recently, pericytes were
identified as major collagen-producing cells in UUO.1 We
found that treatment with BAY PP1 reduced the number of
interstitial mitotic figures, interstitial PCNA-positive, and
interstitial PCNA/PDGFR-b double-positive cells. BAY PP1
had no effect on the proliferation of tubular cells in vivo or in
vitro. However, treatment with BAY PP1 also had no direct
effect on proliferation of renal fibroblasts in vitro. As PPAR-a
is mainly expressed by tubular cells, we hypothesized that
BAY PP1 might have reduced renal fibroblast proliferation via
paracrine effects mediated by tubular cells. In vitro, we found
a significant reduction of the proliferation of fibroblasts that
were incubated with conditioned media from tubular cells
treated with BAY PP1 when compared with those from
untreated tubular cells. TGF-b1, which is known to induce
proliferation and ECM production in fibroblasts, was
supposed to be one of the mediators of these effects. We
Table 3 | Renal fibrosis in obstructed and contralateral kidneys of PPAR-a/ and WT mice with UUO (day 5)
Obstructed kidneys Contralateral kidneys
PPAR-a/ WT PPAR-a/ WT
Kidney weight/bw ( 103) 6.9±0.2 7.4±0.2 7.7±0.4 7.8±0.2
Collagen (Sircol assay) (mg/mg protein) 9.6±1.2 8.9±1.5 5.6±0.8 5.4±0.8
Collagen I (western blot) (AU) 1.1±0.1 1.0±0.1 ND ND
Collagen I (% stained area) 6.2±1.2 4.7±1.2 1.2±0.3 2.7±0.8
Collagen IV (% stained area) 16.0±1.4 16.6±1.8 11.1±2.0 8.9±1.7
Fibronectin (% stained area) 17.3±1.6 17.4±3.3 3.4±0.6 4.2±0.4
F4/80 (% stained area) 4.0±0.6 4.0±1.0 0.68±1.4 0.63±1.3
TGF-b1 mRNA (relative expression) 7.2±3.3 3.7±0.5 2.2±0.6 1.0±0.2
TNF-a mRNA (relative expression) 1.1±0.5 1.5±0.6 0.9±0.2 1.0±0.5
MCP-1 mRNA (relative expression) 3.5±0.6 4.9±1.2 1.0±0.1 1.0±0.2
Abbreviations: AU, arbitrary unit; bw, body weight; MCP-1, monocyte chemotactic protein 1; ND, not determined; PPAR-a, peroxisome proliferator-activated receptor-a;
TGF-b1, transforming growth factor b1; TNF-a, tumor necrosis factor-a; UUO, unilateral ureteral obstruction; WT, wild type.
No significant differences were found between PPAR-a/ and WT in obstructed or contralateral kidneys. For relative expression of mRNA WT contralateral kidney was
set as 1. The densitometry data of collagen type I western blot were normalized to densitometry data of loading control (GAPDH).
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Figure 8 |Conditioned medium from rat tubular cells treated
with BAY PP1 reduced renal fibroblast proliferation. In vitro,
rat renal fibroblasts (NRK-49F) and tubular cells (NRK-52E) were
stimulated for 48 h with full medium (set as 100%), full medium
with the profibrotic cytokine TGF-b1 (50 ng/ml, black bars), and
with full medium with TGF-b1 and the PPAR-a agonist BAY PP1
(1 mmol/l, white bars). BAY PP1 had no direct effect on
proliferation of either (a) fibroblasts or (b) tubular cells.
(c) However, fibroblasts incubated with conditioned media from
tubular cells treated with BAY PP1 had a significantly reduced
proliferation rate (34%) compared with those fibroblasts
incubated with media from untreated tubular cells. Data are
means±s.e.m. Proliferation of full medium without TGF-b1
and BAY PP1 was set as 100%. *Po0.05 vs TGF-b.
BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-(trifluoromethyl)phenyl]
pyrimidin-4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic
acid; PPAR-a, peroxisome proliferator-activated receptor-a;
TGF-b1, transforming growth factor-b1.
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showed here that tubular cells treated with BAY PP1
expressed significantly less TGF-b1 mRNA, and that renal
cortical TGF-b1 expression was markedly reduced by BAY
PP1 treatment in vivo. Thus, our data correspond to previous
studies in glomerular mesangial cells and cardiac and
hepatic fibrosis/fibroblasts in which PPAR-a agonists
reduced the proliferation of fibroblasts and decreased ECM
deposition and TGF-b1 expression.
9,10,12,14–17 However, our
in vivo and in vitro data suggest that, in the kidneys, these are
not direct effects on fibroblasts, but rather on tubular
epithelial cells. Taken together, treatment of tubular cells with
the PPAR-a agonist stabilized the epithelial phenotype and
reduced the production of ECM proteins and of factors
affecting proliferation of interstitial fibroblasts (for example,
of TGF-b1).
Previous studies in models of diabetic, toxic, or ische-
mia–reperfusion kidney injury suggested that the reno-
protective properties of PPAR-a might be related to cell
metabolism, inflammation, and apoptosis.7–9,11–13 Both
UUO- and remnant kidney model are characterized by
increased proliferation and apoptosis of tubular epithelial
cells and by a significant infiltration of inflammatory cells.20
In our study, there were no differences in systemic or renal
inflammatory markers between the groups. Interestingly,
there was also no observable effect on tubular proliferation or
apoptosis.
Compared with other studies, we have used a similar or
even a slightly higher dose of fenofibrate in the UUO
model.10,15,16 Nevertheless, we found no effect of fenofibrate
on renal fibrosis. Thus, unlike BAY PP1, fenofibrate was not
effective locally in the obstructed kidneys. In line with this,
we found only very slight effects of fenofibrate on the
expression of PPAR-a, whereas BAY PP1 showed robust
effects. Fenofibrate accumulates highly in the liver, resulting
in lower levels in renal tissue (see Najib30 and Bayer Schering
Pharma, unpublished data). In contrast, BAY PP1 has no
hepatic accumulation and a more balanced distribution
between the liver and other organs (Bayer Schering Pharma,
unpublished data). Thus, the much lower potency and
imbalanced distribution of fenofibrate in comparison with
BAY PP1 is most likely the reason for the different efficacy of
both compounds locally in kidneys.
In conclusion, we could demonstrate, in two models of
renal fibrosis, that PPAR-a is significantly downregulated in
tubular cells. Treatment with potent PPAR-a agonist
significantly restores PPAR-a expression and ameliorates
renal fibrosis. This seems to be mediated by direct effects on
tubular cells, for example, by reducing their production of
ECM proteins, and also indirectly by modulation of the
cross-talk between tubular cells and interstitial fibroblasts.
Potent PPAR-a agonists could represent a novel treatment
approach in patients with renal fibrosis. Furthermore, we
found no indications of adverse effects in overall appearance,
nonobstructed kidneys, plasma biochemistry, or blood
counts.
MATERIALS AND METHODS
PPAR-a agonists
Fenofibrate was purchased from Sigma-Aldrich (Deisenhofen,
Germany). BAY PP1, was obtained from Bayer Schering Pharma
AG (Wuppertal, Germany).
Brief description of the test system. A chimeric system was
used, in which the ligand-binding domain (LBD) of the human
PPAR protein is fused to the DNA-binding domain (DBD) of the
yeast transcription factor GAL4. The GAL4-PPAR-a, -g, or -d LBD
fusion construct, plus a reporter construct containing GAL4-binding
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Figure 9 | Expression of PPAR-a in renal fibroblasts and tubular cells in vitro. In vitro, rat renal fibroblasts (NRK-49F) and tubular
cells (NRK-52E) were stimulated for 48 h with full medium, full medium with the profibrotic cytokine TGF-b1 (50 ng/ml, black bars), and with
full medium with TGF-b1 and the PPAR-a agonist BAY PP1 (1 mmol/l, white bars). (a, c) In renal fibroblasts, no PPAR-a expression could be
found in either of the stimulations using western blotting. (b, d) In renal tubular cells, on the other hand, cells in full medium expressed
PPAR-a and addition of TGF-b1 reduced its expression by 31%. Furthermore, treatment with BAY PP1 significantly increased PPAR-a
expression in tubular cells. Data are means±s.e.m. Data on western blotting show relative optical intensity (densitometry); expression
in cells incubated with full medium without TGF-b1 and BAY PP1 was arbitrarily set as 100%. **Po0.01 vs. TGF-b. BAY PP1, 2-[(4-{[(2-
Methoxyethyl){6-[3-(trifluoromethyl)phenyl]pyrimidin-4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; ND, not detectable
(that is, under the detection limit); PPAR-a, peroxisome proliferator-activated receptor-a; TGF-b1, transforming growth factor-b1.
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sites in front of the luciferase gene, were co-transfected and stably
expressed in CHO (CHO-K1, ATCC CCL61) cells. The PPAR-LBD-
mediated induction of luciferase gene expression correlates with
relative light units detected by a standard luciferase assay.
Cloning of human PPAR-LBD-GAL4 vector constructs. Three
human PPAR isoforms have been cloned for specificity testing. The
GAL4-PPAR-a LBD and GAL4-PPAR-g LBD expression constructs
contain the LBD of PPAR-a (amino acids 167–468, National Center
for Biotechnology Information (NCBI) accession no. L02932) and
PPAR-g (amino acids 203–506, NCBI accession no. AB005526),
respectively. The human GAL4-PPAR-d expression construct con-
tains the LBD of PPAR-d (amino acids 138–442). The LBD receptor
fragments were amplified by PCR and cloned into the pcDNA3.1-
GAL4-DBD vector downstream of the GAL4-DBD. This vector
contains the GAL4-DBD (amino acids 1–147) of the pFC2-dbd
vector (Stratagene, La Jolla, CA). The reporter construct, pFRLuc
(Stratagene), which contains five copies of the GAL4-binding site in
front of the minimal thymidine kinase promoter, leads to the
expression of the firefly luciferase (Photinus pyralis) after activation
of the PPAR LBD-GAL4 fusion proteins by ligand binding.
Transactivation assays using human PPAR-LBD-GAL4-ex-
pressing CHO cells. Stably transfected CHO cells (GAL4-PPAR-
a, GAL4-PPAR-g, or GAL4-PPAR-d) were seeded in Optimem
media (Invitrogen, Darmstadt, Germany) containing 2% delipidated
serum (Hyclone, Logan, UT), 1.35mmol/l sodiumpyruvate (In-
vitrogen), and 0.2% sodium bicarbonate (Invitrogen). At 1 day
before the testing, 1 103 cells per well (50 ml) were seeded on a 96-
well plate format (Greiner, Frickenhausen, Germany). After cultiva-
tion for 24 h in a CO2 incubator (96% humidity, 5% v/v CO2,
37 1C), the medium was replaced by the serum-free medium (50 ml).
BAY PP1 was dissolved in dimethyl sulfoxide and diluted in
medium. The final test concentrations were 3 and 1 mmol/l, and 300,
100, 30, 10, and 3 nmol/l (each concentration in duplicate).
Fenofibrate was tested in concentrations of up to 300mmol/l. The
Rat tubular cells (NRK-52E) Rat renal fibroblasts (NRK-49F)
TGF-β1 (50 ng/ml)
TGF-β1 mRNA α-SMA mRNA α-SMA mRNACell death
Collagen
BAY PP1:
BAY PP1: BAY PP1:
BAY PP1:
*
*
*
Co
lla
ge
n/
pr
ot
ei
n
R
el
at
. e
xp
re
ss
io
n
M
ed
iu
m
 L
DH
 (O
D)
R
el
at
. e
xp
re
ss
io
n
R
el
at
. e
xp
re
ss
io
n
R
el
at
. e
xp
re
ss
io
n
Fi
br
on
ec
tin
/p
ro
te
in
R
el
at
. e
xp
re
ss
io
n
Co
lla
ge
n/
pr
ot
ei
n
R
el
at
. e
xp
re
ss
io
n2 14 3 14 1.2
0.6
0
7
0
22
11
0
2.6
1.3
0
2
1
0
7
0
1
3
2
1
0
1.2
0.6
0
2
1
0
0
– +
– +
* *
– +
– +
– +
– + – + – +
– + – +
Fibronectin Fibronectin
mRNA
Collagen Collagen I mRNA
TGF-β1 (50 ng/ml)TGF-β1 1 μmol/l BAY PP1
TGF-β1 mRNA
TGF-β1 1 μmol/l BAY PP1
a
c
f g h m n
d e k l
b i j
Vehicle (n=3) BAY PP1 (n=3)
Figure 10 |BAY PP1 treatment of rat tubular cells reduced the production of extracellular matrix (ECM) and TGF-b1 but had no
direct effects on rat renal fibroblasts. The in vitro effect of conditioned media of BAY PP1-treated tubular cells on fibroblasts led us
to investigate the effects of BAY PP1 on the production of ECM and profibrotic factors in rat renal tubular cells (NRK-52E) stimulated for
48 h with TGF-b1 (50 ng/ml). Addition of PPAR-a agonist BAY PP1 (1 mmol/l) had no effect on overall morphology of the (a, b) tubular cells,
but led to a significant decrease in collagen production assessed by (c) Sircol assay, fibronectin expression on the (d) protein and (e) mRNA
level, and (f) TGF-b1 and (g) a-SMA mRNA expression. (h) Lactate dehydrogenase (LDH) release to medium as a measure of cell death
was similar in BAY-treated and untreated cells. To analyze whether BAY PP1 might have direct effects on fibroblasts in vitro, rat renal tubular
fibroblasts (NRK-49F) were stimulated for 48 h with TGF-b1 (50 ng/ml). Addition of the PPAR-a agonist BAY PP1 (1 mmol/l) had no effect on
(i, j) overall morphology of the cells and no effect on (k) collagen production or (l) collagen mRNA expression, as well as no effect on
(m) a-SMA mRNA and (n) TGF-b1 mRNA expressions. Data are means±s.e.m. Original magnification  100. Data of collagen and fibronectin
expression were normalized to total protein content in the medium. LDH release to medium show data relative to full medium without
TGF-b1 and BAY PP1 (arbitrarily set as 1). Data on mRNA expressions show fold change; full medium without TGF-b1 and BAY PP1 was
arbitrarily set as 1. *Po0.05 vs TGF-b1. a-SMA, a-smooth muscle actin; BAY PP1, 2-[(4-{[(2-Methoxyethyl){6-[3-(trifluoromethyl)phenyl]
pyrimidin-4-yl}amino]methyl}phenyl)sulfanyl]-2-methylpropanoic acid; PPAR-a, peroxisome proliferator-activated receptor-a; TGF-b1,
transforming growth factor-b1.
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compounds were directly added to the cells (double concentration
in 50 ml) and luciferase activity was measured after 6 h of incubation
with a video camera system. The measured relative light units led to a
sigmoid dose–response curve with increasing compound concentra-
tions. EC50 values were calculated from dose–response curves using the
computer program GraphPad PRISM (Version 3.02) (La Jolla, CA).
Experimental model and design
The investigation was conducted according to the guidelines for
studies using laboratory animals (86/609/EEC), after approval of
the protocol by the State Veterinary and Food Administration
(Bratislava, Slovakia). Male Wistar rats (Charles River, Budapest,
Hungary) and male PPAR-a/ and WTmice were housed in rooms
with constant temperature and humidity, 12/12 h light/dark cycle,
with ad libitum access to drinking water and food (SP1, Top Dovo,
Czech Republic).
After 1 week of acclimatization (Figure 1a), rats (weighing
271±18 g) were subjected to UUO (n¼ 21) or sham operation
(n¼ 6) under intraperitoneal injection of ketamin/xylazin narco-
sis.22 At 1 day before the operation, the rats were randomized
into four groups: sham-operated group receiving vehicle (10%
ethanol in 1% hydroxyethylcellulose, SHAM, n¼ 6), control group
receiving vehicle (CTRL, n¼ 7), group receiving the PPAR-a agonist
fenofibrate (50mg/kg body weight per day, FF, n¼ 7), and group
receiving the PPAR-a agonist, BAY PP1 (4mg/kg body weight per
day, BAY, n¼ 7). All the treatments were administered daily, in the
morning (between 0900 and 1000 hours) by gavage. The treatment
started 1 day before disease induction and ended before killing
the animals on day 5. The dosages were chosen on the basis of
previous studies showing antifibrotic effects of fenofibrate10,15,16 and
of BAY PP1 in heart failure models in rats (Barbara Albrecht-
Ku¨pper, unpublished data) and rabbits (Antonius Baartscheer and
Barbara Albrecht-Ku¨pper, unpublished data). At the time of killing
the animals on day 5, blood was sampled from the abdominal aorta.
Both the obstructed and contralateral unobstructed kidneys were
harvested, weighed, and processed for histological and biochemical
evaluation and RNA isolation.
After 1 week of acclimatization (Figure 5a), rats (weighing
228±15 g) were subjected to ablation of 2/3 of the renal parenchyma
of the left kidney, followed by a nephrectomy of the contralateral
kidney 14 days thereafter (n¼ 18), both under intraperitoneal
injection of ketamin/xylazin narcosis. Sham (SHAM, n¼ 4) rats were
operated in parallel. On day 42 after the second operation, the rats
with remnant kidneys were randomized into two groups: receiving
vehicle (10% ethanol in 1% hydroxyethylcellulose, PLAC, n¼ 7) or
the PPAR-a agonist BAY PP1 (4mg/kg body weight day, BAY, n¼ 9).
Rats were treated daily by gavage for 17 days, in the morning
(between 0900 and 1000hours). Two rats from the placebo group
died during the experiment for unknown reasons. Blood sampling
from the tail vein was performed 5 days before uninephrectomy and
on day 39 (3 days before start of treatment). At 1 day before killing
the animals, blood pressure was measured using tail plethysmography,
as described previously.31 At the time of killing the animals on day 59,
blood was sampled from the abdominal aorta and the remnant
kidneys were harvested, weighed, and processed for histological and
biochemical evaluation, and RNA isolation.
Eight-week-old male PPAR-a deficient mice (weighing
23.9±1.4 g) or WT mice (weighing 20.6±1.2g; n¼ 8), all on a
C57Bl/6 background, were purchased from TACONIC (Laven,
Denmark). After 1 week of acclimatization, all mice underwent
UUO.22 At the time of killing the animals on day 5, both the
obstructed and contralateral unobstructed kidneys were harvested,
weighed, and processed for histological and biochemical evaluation,
and RNA isolation.
Renal morphology and immunohistochemistry
For the evaluation of renal histology and fibrosis, renal tissue was
stained with periodic acid Schiff in 4 mm sections of kidney biopsies,
fixed in methyl Carnoy’s solution, and embedded in paraffin.
The number of interstitial and tubular mitoses was counted in 20
consecutive view fields at  400. Tubulointerstitial score was graded
on a scale from 0 to 4, as described previously.31 In short, for each
animal, the extent of renal cortex with fibrosis, tubular atrophy/
dilation, and inflammatory infiltrates was scored as follows: 0, up
to 5%; 1, 6–25%; 2, 26–50%; 3, 51–75%; and 4, 76–100%.
The indirect immunoperoxidase procedure was performed as
described previously.22,31,32 The following primary antibodies were
used: murine monoclonal antibody (clone 1A4) to human a-SMA
directly coupled with horseradish peroxidase (HRP; dilution 1:500;
DAKO A/S, Glostrup, Denmark); murine monoclonal IgG antibody
(clone ED-1) to monocytes, macrophages, and dendritic cells, and
goat polyclonal antibodies to human collagen types I, III, and IV
(dilutions 1:500, 1:100, 1:100, and 1:200, respectively, all from
Southern Biotechnology Associates, Birmingham, AL); rabbit
polyclonal antibody to rat fibronectin (Chemicon, Temecula, CA;
dilution 1:100); rat anti-mouse F4/80 (dilution 1:800, Serotec,
Du¨sseldorf, Germany); monoclonal antibody to human PCNA
(dilution 1:1000; Oncogene Science, Cambridge, MA); and mono-
clonal antibody to human PDGFR-b (dilution 1:20, R&D Systems,
Minneapolis, MN). All secondary antibodies used were biotinylated
and affinity purified (Vector, Burlingame, CA). All antibodies were
crossreactive with appropriate rat and mice proteins.31,32 Negative
controls were performed as previously described.22,32 To detect
PCNA/PDGFR-b double-positive cells, the sections were first stained
with monoclonal antibody to PCNA and visualized as brown
diaminobenzidine product, followed by antigen retrieval with the
Trilogy system (Cell-Marque, Rocklin, CA, Cat. No. 920P-06), and
they were then stained with antibody against PDGFR-b and
visualized as blue product with Vector blue kit.
For PPAR-a staining, methyl Carnoy’s solution-fixed and
paraffin-embedded kidney sections were deparaffinized in xylene
and rehydrated in graded ethanols, washed in phosphate-buffered
saline (PBS), blocked in 1% goat serum, and incubated with rabbit
anti rat PPAR-a antibody (dilution 1:100, Abcam, Cambridge, UK)
for 1 h at room temperature. After PBS washes, sections were
incubated with anti-rabbit Cy3 antibody (dilution 1:400) in the
dark, followed by PBS washes and counterstaining with 4,6-
diamidino-2-phenylindole.
Staining for apoptotic cells was performed using a commercially
available kit based on TUNEL (terminal transferase-mediated
X-dUTP nick-end labeling) (In situ Cell Death Detection Kit,
Fluorescein, Cat. No. 11 684 795 001, Roche Applied Science,
Mannheim, Germany). The assay uses an optimized terminal
transferase to label free 30OH ends in genomic DNA with
fluorescein-dUTP or TMR-dUTP. Briefly, methyl Carnoy’s
solution-fixed and paraffin-embedded kidney sections were depar-
affinized in xylene and rehydrated in graded ethanols. Histological
sections were pretreated for 20min at 37 1C with 20 mg/ml
proteinase K (Cat. No. 03 115 836 00, Roche Applied Science).
Following washing steps in PBS, the TUNEL assay was performed
according to the manufacturer’s instructions. Negative controls were
performed according to the manufacturer’s instructions. Stained
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sections were analyzed with a fluorescence microscope (Leica
DM6000 B, Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany)
by counting the number of positive (apoptotic) tubulointerstitial
nuclei in 30 consecutive high-power fields ( 400) for each section.
All histological and immunohistochemical evaluations were
performed in a blinded manner by an observer who was unaware
of the origin of the slides. To evaluate the area stained by specific
antibodies, computer-based morphometry (Soft Imaging System,
GmbH, Mu¨nster, Germany) was performed as described pre-
viously.22,31,32 The percentage of positively stained area was
calculated from 20 cortical fields (0.093mm2 each) per section,
representing nearly the whole cortex. Interstitial ED-1 cells were
counted in 20 view fields at  400 magnification and were expressed
as the number of ED-1-positive cells. PCNA-positive cortical
interstitial and tubular cells were counted in 10 view fields at
 600. PCNA and PDGFR-b double-positive cells were evaluated in
10 interstitial view fields at  600 magnification.
Western blotting
Snap-frozen renal cortical samples (B3mm 3mm 3mm) were
homogenized in 0.8ml protein extraction buffer including a protease
inhibitor cocktail (Sigma). After incubation for 5min on ice, the
samples were subjected to ultrasound treatment (3 100 0) and
centrifuged for 5min at 13,000 r.p.m. The supernatant was assayed
for protein content using the BCA protein assay according to the
manufacturer’s instructions (Uptima, Montlucon, France; Cat. No.
UP40840B). Electrophoresis under denaturing conditions on a 4–12%
NuPAGE gradient gel (Invitrogen) was performed using equal protein
load per lane. Thereafter, the proteins were transferred onto
nitrocellulose membranes, blocked overnight in 5% milk in TTBS
(150mmol/l NaCl, 10mmol/l Tris, pH 8.0, 0.05% (v/v) Tween 20),
washed, and incubated with anti-PPAR-a antibody (1:2000; Novus
Biologicals, Littleton, CO) or anti-collagen type I antibody (1:2000;
Southern Biotechnology Associates) for 2 h. After several washes,
membranes were incubated with anti-rabbit or anti-goat HRP-
conjugated IgG antibodies (1:5000), respectively, washed, and
visualized using the ECL reagent (Thermo Fischer Scientific, Rockford,
IL). Densitometry was carried out using the QuantityOne software
(Bio-Rad, Herts, UK). For loading control, the membranes were
stripped in stripping buffer (62.5mmol/l Tris-HCl, pH 6.8, 2% sodium
dodecyl sulfate, 0.685% b-mercaptoethanol) at 56 1C for 30min,
washed three times in TTBS, blocked for 1 h at room temperature,
and incubated with mouse monoclonal anti-GAPDH antibody (clone
1D4, 1:5000, Novus Biologicals). As secondary antibody, a goat HRP-
conjugated anti-mouse IgG (Hþ L) antibody (dilution 1:10,000) was
used. All other steps were identical to the above-described western blot
procedures.
Biochemical analyses
Blood counts (Sysmex K-21 Analyzer, Kobe, Japan) and standard
blood chemistry parameters in plasma (Vitros 250 analyzer, J&J,
Rochester, NY) were measured. Plasma tumor necrosis factor-a
and interleukin-6 (both rat-specific enzyme-linked immunosorbent
assay (ELISA), Bender MedSystems, Vienna, Austria; Cat. No.
BMS622 and BMS625, respectively) concentrations were analyzed
using commercially available kits according to the manufacturer’s
instructions. Collagen production in vitro and in renal cortical
lysates was analyzed using Sircol assay according to the manu-
facturer’s instructions (Biocolor, Carrickfergus, UK; Cat. No.
S1000). TGF-b1 was measured by an ELISA (R&D Systems; Cat.
No. MB100B) according to the manufacturer’s instructions,
including the activation of latent TGF-b1 by acidification. Plasma
concentration of advanced oxidation protein products was mea-
sured as described previously.32
RNA extraction and analyses
Total RNA was extracted from the renal cortex using the standard
Trizol protocol (MRC, Cincinnati, OH; Cat. No. RT111);
the concentration and the purity of RNA were measured spectro-
photometrically using Nanodrop (NanoDrop Technologies,
Wilmington, DE) as described previously.32 For real-time PCR, the
Qiagen QuantiFast Sybr Green RT-PCR kit (Qiagen, Hilden,
Germany; Cat. No. 204154) was used according to the manufac-
turer’s instructions. For normalization of the data, the standard
DCt method was used with peptidylprolyl isomerase A (cyclophilin
A) for in vivo experiments and GAPDH (glyceraldehyde
3-phosphate dehydrogenase) for in vitro experiments as the house-
keeping genes. The expression of the genes of interest was calculated
as relative fold change in expression in comparison with the sham-
operated (in vivo) or unstimulated group (in vitro), arbitrarily
set as 1. Primers used for real-time PCR are shown in Table 4.
Cell culture experiments
The rat renal fibroblast cell line, NRK-49F, and the rat renal
epithelial cell line, NRK-52E, were cultured as described previously
and according to the instructions of the German National Resource
Center for Biological Material (Braunschweig, Germany).31 To
examine the effects of BAY PP1 on cell proliferation, NRK-49F
and NRK-52E were seeded in 96-well plates, grown to subcon-
fluency, and then stimulated for 48 h in full growth medium with
Table 4 | Primers for gene expression analysis using real-time PCR used in this study (all 5030)
Gene/gene ID Forward primer Reverse primer Species
ppia/25518 GTCTCTTTTCGCCGCTTGCT TCTGCTGTCTTTGGAACTTTGTCTG Rat
col1a1/29393 CAACCTCAAGAAGTCCCTGC ACAAGCGTGCTGTAGGTGAA Rat
fn1/25661 CAAGGTCCGAGAAGAGGTTG CCGTGTAAGGGTCAAAGCAT Rat
vim/81818 AATGCTTCTCTGGCACGTCT GCTCCTGGATCTCTTCATCG Rat
acta/81633 TTCAATGTCCCTGCCATGTA CATCTCCAGAGTCCAGCACA Rat
tgfb1/59086 GAAGGACCTGGGTTGGAAGT TACTGTGTGTCCAGGCTCCA Rat
mpo/303413 GGAAGTGGCGAACTCAGTGG AGGAGTTCCATAGGGCTGGC Rat
ppia/268373 TTCGAGCTCTGAGCACTGG CCAGTGCCATTATGGCGT Mouse
tgfb1/21803 GGAGAGCCCTGGATACCAAC ACTTCCAACCCAGGTCCTTC Mouse
tnfa/21926 GTCCCTTTCACTCACTGGCC GAGTGCCTCTTCTGCCAGTTC Mouse
mcp1/20296 CCTACAACTTTATTTAAAACTGCATCTG CTAGTTCACTGTCAACTGGTCACTC Mouse
Abbreviations: acta, a-smooth muscle actin; col1a1, collagen type I a1 chain; fn1, fibronectin 1; mcp1, monocyte chemotactic protein 1; mpo, myeloperoxidase; ppia, peptidylprolyl
isomerase A (cyclophilin A); tgfb1, transforming growth factor-b1; vim, vimentin.
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or without the profibrotic cytokine TGF-b1 (50 ng/ml, Sigma-
Aldrich) and with or without BAY PP1 (1mmol/l). DNA synthesis
was determined by a 5-bromo-20-deoxyuridine incorporation assay
according to the manufacturer’s instructions (Roche; Cat. No.
QIA58-200TEST).31 To examine the expression of collagens,
fibronectin, and TGF-b1, NRK-49F and NRK-52E were seeded in
12-well plates. After 24 h, these cells were stimulated for 48 h in
full growth medium with or without the profibrotic cytokine
TGF-b1 (50 ng/ml, Sigma-Aldrich) and with or without BAY PP1
(1mmol/l). Cell medium was collected and cells were harvested
and RNA isolated as described previously.31 In cell culture medium,
collagen production was analyzed using Sircol assay (Biocolor;
Cat. No. S1000) according to the manufacturer’s instructions.
Fibronectin was assessed in cell medium by an ELISA. In brief,
96-well plates were coated overnight at 4 1C with medium or
fibronectin standard curve (Sigma, Vienna, Austria). All wells were
then washed four times with PBS/Tween 0.05%, then blocked with
2% bovine serum albumin/PBS for 60min, washed again, then
incubated for 60min with rabbit anti-rat fibronectin antibody
(1:1000, Chemicon), washed again, then incubated for 60min
with peroxidase coupled anti-rabbit antibody (1:1000, Vector
Laboratories), washed again, and finally incubated for 15min with
substrate ABTS. The absorbance was determined at 450 nm using
the 96-well plate reader, Sunrise (Tecan, Ma¨nnedorf, Switzerland).
CytoTox 96 Cytotoxicity Assay was used according to the manu-
facturer’s instructions (Promega, Madison, WI; Cat. No. G1780). To
examine the expression of PPAR-a in renal cells in vitro, NRK-49F
and NRK-52E were grown to subconfluency in 25mm3 cell culture
flasks and stimulated for 48 h in full growth medium with or
without the profibrotic cytokine TGF-b1 (50 ng/ml) and with or
without BAY PP1 (1mmol/l). Thereafter, cells were harvested and
proteins were isolated for PPAR-a western blotting (see above). All
in vitro experiments were performed in triplicate.
Statistical analysis
All values are expressed as mean±s.e.m. Kruskal–Wallis H-test,
analysis of variance for multiple-group comparison, unpaired
Student’s t-test, or Mann–Whitney U-test for two-group comparison
were used where appropriate after testing for distribution. For
comparison of different fibrosis parameters, Spearman’s coefficient
of correlation was calculated. All tests were two tailed. Statistical
significance was defined as Po0.05.
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